Halozyme Therapeutics, Inc. (HALO) — Stock Price, Chart & Analysis
Halozyme Therapeutics, Inc. (HALO) is a Healthcare stock currently trading at $100, up 0.00% on the day. It carries a market capitalization of $12.23B and a trailing P/E ratio of 36.18. Over the past 52 weeks, HALO has traded between $61.23 and $103.30. Halozyme Therapeutics, Inc. does not currently pay a regular dividend. View the live HALO chart, technical opinion, analyst ratings, fundamentals and latest news below.
Halozyme Therapeutics, Inc. (HALO) key data
| Price | $100 |
| Change (today) | +0.00% |
| Previous close | $100 |
| Market cap | $12.23B |
| P/E ratio (TTM) | 36.18 |
| EPS (TTM) | $2.85 |
| 52-week high | $103.30 |
| 52-week low | $61.23 |
| Beta | 0.85 |
| Avg. volume | 1.99M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Halozyme Therapeutics, Inc. (HALO)
How much does one share of Halozyme Therapeutics, Inc. cost?
As of the latest update, one share of Halozyme Therapeutics, Inc. (HALO) trades at $100 (+0.00% today).
What is Halozyme Therapeutics, Inc.'s market cap?
Halozyme Therapeutics, Inc. has a market capitalization of approximately $12.23B.
What is Halozyme Therapeutics, Inc.'s P/E ratio?
Halozyme Therapeutics, Inc. has a trailing price-to-earnings (P/E) ratio of 36.18.
What is Halozyme Therapeutics, Inc.'s earnings per share (EPS)?
Halozyme Therapeutics, Inc.'s trailing twelve-month EPS is $2.85.
Does Halozyme Therapeutics, Inc. pay a dividend?
Halozyme Therapeutics, Inc. does not currently pay a regular dividend.
What is Halozyme Therapeutics, Inc.'s 52-week trading range?
Over the past year, HALO has traded between $61.23 and $103.30.
What is the analyst price target for Halozyme Therapeutics, Inc.?
The mean analyst price target for Halozyme Therapeutics, Inc. is $88.22. This is informational only and not investment advice.
Latest Halozyme Therapeutics, Inc. (HALO) news
- Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...News · Aug 8, 2026
- Stock Market Today: Nasdaq Leaps As Fed Rate-Hike Odds Sink; Biotech Jumps 20%, Sezzle Fizzles OutNews · Aug 7, 2026
- Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish VolumeNews · Aug 7, 2026
- These Two Biotech Stocks Hit Fresh 52-Week Highs Today – NTRA Clocks Best Day In Nearly 20 MonthsNews · Aug 7, 2026
- Halozyme Therapeutics Q2 Earnings Call HighlightsNews · Aug 7, 2026
- Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key MetricsNews · Aug 6, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live HALO dashboard…